Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study

References

• Orimo H, Hashimoto T, Sakata K, et al. Trends in the incidence of hip fracture in Japan, 1987–1997: the third nationwide survey. J Bone Miner Metab 2000;18:126-31
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Muraki S, Oka H, et al. Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 2009;27:620-8
   PubMed Web of Science ®Google Scholar
• Iki M. Aim of the Guidelines for the Prevention and Treatment of Osteoporosis (2011 edition). Epidemiology of osteoporosis in Japan. Clin Calcium 2012;22:797-803
   PubMedGoogle Scholar
• Andersen SJ. Osteoporosis in the older woman. Clin Obstet Gynecol 2007;50:752-66
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt) 2009;18:1615-26
   PubMed Web of Science ®Google Scholar
• Silverman SL, Piziak VK, Chen P, et al. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 2005;32:2405-9
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Rajzbaum G, Jakob F, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85:484-93
   PubMed Web of Science ®Google Scholar
• Nakamura T. The Japanese Guidelines for the Prevention and Treatment of Osteoporosis (2006 Edition) and its significance. Nippon Rinsho 2007;65(Suppl):29-34
   PubMedGoogle Scholar
• Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
   Google Scholar
• Gallagher JC, Levine JP. Preventing osteoporosis in symptomatic postmenopausal women. Menopause 2011;18:109-18
   PubMed Web of Science ®Google Scholar
• Yoh K, Tanaka K, Ishikawa A, et al. Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab 2005;23:167-73
   PubMed Web of Science ®Google Scholar
• Kushida K, Fukunaga M, Kishimoto H, et al. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: A randomized, double-masked trial. J Bone Miner Metab 2004;22:469-78
   PubMed Web of Science ®Google Scholar
• Cranney A, Adachi JD. Benefit–risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf 2005;28:721-30
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010;47:729-35
   PubMed Web of Science ®Google Scholar
• Messalli EM, Scaffa C. Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: An update. Int J Womens Health 2010;1:11-20
   PubMedGoogle Scholar
• Ringe JD, Muhlenbacher D, Beck H. Diagnosis and therapy of osteoporosis in medical practice in Germany – a survey of 5902 female patients with osteoporosis prior to and after raloxifene treatment. Osteologie 2003;12:23-30
   Google Scholar
• Scharla S, Oertel H, Helsberg K, et al. Skeletal pain in postmenopausal women with osteoporosis: Prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Curr Med Res Opin 2006;22:2393-402
   PubMed Web of Science ®Google Scholar
• Ringe JD, Christodoulakos GE, Mellstrom D, et al. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin 2007;23:2677-87
   PubMed Web of Science ®Google Scholar
• Ozgocmen S, Kaya H, Fadillioglu E, et al. Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Arch Med Res 2007;38:196-205
   PubMed Web of Science ®Google Scholar
• Lips P, Cooper C, Agnusdei D, et al. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int 1999;10:150-60
   PubMed Web of Science ®Google Scholar
• Evista [package insert]. Kobe, Japan: Eli Lilly Japan K.K. and Chugai Pharmaceutical Co. Ltd, 2007
   Google Scholar
• Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001;19:331-7
   PubMed Web of Science ®Google Scholar
• Ware JE, Kosinski M, Dewey JE, et al How to score and interpret single-item health status measures: a manual for users of the SF-8 health survey. Lincoln, RI: Quality Metric Inc., 2001
   Google Scholar
• Fukuhara S, Suzukano Y. Manual of the SF-8 Japanese Version (in Japanese). Kyoto, Japan: Institute for Health Outcomes and Process Evaluation Research, 2004
   Google Scholar
• The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
   PubMed Web of Science ®Google Scholar
• Japanese EuroQol translation team. The development of the Japanese EuroQol instrument. Shakaitorinsho 1998;8:109-17
   Google Scholar
• Takahashi H. Assessment of health related quality of life in osteoporotic patients. Nippon Rinsho 2002;60(Suppl 3):479-84
   PubMedGoogle Scholar
• Kumamoto K, Nakamura T, Suzuki T, et al. Validation of the Japanese Osteoporosis Quality of Life Questionnaire. J Bone Miner Metab 2010;28:1-7
   PubMed Web of Science ®Google Scholar
• Ostelo RW, de Vet HC. Clinically important outcomes in low back pain. Best Pract Res Clin Rheumatol 2005;19:593-607
   PubMed Web of Science ®Google Scholar
• Suka M, Yoshida K. Low back pain deprives the Japanese adult population of their quality of life: a questionnaire survey at five healthcare facilities in Japan. Environ Health Prev Med 2008;13:109-15
   PubMedGoogle Scholar
• Fujita T, Fujii Y, Munezane H, et al. Analgesic effect of raloxifene on back and knee pain in postmenopausal women with osteoporosis and/or osteoarthritis. J Bone Miner Metab 2010;28:477-84
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ito M, Iwayama S, et al. Interim report: effect of risedronate (Actonel) tablet 17.5 mg on improving quality of life for osteoporosis patients in post-marketing surveillance. Igaku to Yakugaku 2010;63:889-903
   Google Scholar
• Haegerstam GA. Pathophysiology of bone pain: a review. Acta Orthop Scand 2001;72:308-17
   PubMed Web of Science ®Google Scholar
• Viereck V, Grundker C, Blaschke S, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 2003;88:4206-13
   PubMed Web of Science ®Google Scholar
• Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005;208:207-27
   PubMed Web of Science ®Google Scholar
• Treede RD. The physiology of bone pain. Osteologie 1999;4:195-200
   Google Scholar
• Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10
   PubMed Web of Science ®Google Scholar
• Naylor KE, Clowes JA, Finigan J, et al. The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone 2010;46:592-7
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
   PubMed Web of Science ®Google Scholar
• Bouchet C, Guillemin F, Briancon S. Nonspecific effects in longitudinal studies: impact on quality of life measures. J Clin Epidemiol 1996;49:15-20
   PubMed Web of Science ®Google Scholar
• Marquis P, Roux C, de la Loge C, et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int 2008;19:503-10
   PubMed Web of Science ®Google Scholar
• Iikuni N, Hamaya E, Nihojima S et al. Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance. J Bone Miner Metab 2012: published online 2 July 2012, doi: 10.1007/s00774-012-0365-1
   Google Scholar